ARTICLE | Product Development
Pharmas challenging Novo and Lilly in obesity
An analysis of which major pharmas are in, out, or still deciding whether to take on obesity heavyweights Eli Lilly and Novo Nordisk
November 15, 2024 10:20 PM UTC
Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.
Eli Lilly and Novo Nordisk have clearly set themselves apart from other pharmas in the scale of their pipelines, revenues and business development activities in obesity. But with what is projected to be the largest-ever market opportunity, other pharmas aren’t sitting this one out. Or are they? ...